Zealand Pharma CEO: Zegalogue launch continues as planned

The seminal launch of hypoglycemia medication Zegalogue has thus far gone according to plan, informs biotech group Zealand Pharma CEO Emmanuel Dulac, who declines to disclose figures for the development thus far, however.

Photo: Stine Bidstrup/ERH

It's nearly two months back since last June when Zealand Pharma launched its hypoglycemia medication, Zegalogue, on the US market. According to the Danish biotechnology group's chief executive, Emmanuel Dulac, everything is going completely according to plan.

"We are very satisfied with the way things are going, Engagement is very high, motivation is high, and activity is high," Dulac tells MedWatch in connection with the release of Zealand's second-quarter interim report Thursday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs